Receptor News and Research

RSS

Study compares NAbs from natural SARS-CoV-2 infection vs. vaccine induced against symptomatic infection

Scientists have recently compared the levels of antibody concentrations in unvaccinated, SARS-CoV-2 convalescent individuals and COVID-19 specific antibodies in vaccinated individuals.

30 Nov 2021

An antiviral regimen based on biomimetic polymers for COVID-19

In a new study published on the bioRxiv* preprint server, scientists proposed the aforementioned mechanism of action (MOA) and have validated it using electron photomicrographs of murine cytomegalovirus (MCMV), which were incubated with a nanoviricide.

30 Nov 2021

Northwestern researchers continue to tackle every facet of COVID-19 pandemic

As the COVID-19 pandemic nears the two-year mark, Northwestern Medicine scientists continue to tackle every facet of the disease, from investigating coronavirus vaccines' potential for providing immunity against similar coronaviruses to developing novel rapid antigen-based tests and examining disparities in COVID-19 case and mortality rates in Chicago.

30 Nov 2021

Prior infection with SARS-CoV-2 continues to provide protection from reinfection

Researchers from the University of Michigan investigated the correlation between SARS-CoV-2 infection and the severity of reinfections.

30 Nov 2021

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

30 Nov 2021

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

New phenotype of LRP6 mutation reported for the first time in patients with tooth agenesis

A group led by Prof. Han Dong of Peking University School of Stomatology reported for the first time hand preaxial polydactyly in patients with tooth agenesis carrying a previously unknown mutation of low-density lipoprotein receptor-related protein 6 (LRP6).

29 Nov 2021

An update of what is currently known about Omicron

On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO's Technical Advisory Group on Virus Evolution (TAG-VE).

29 Nov 2021

Heart failure patients may benefit from common type 2 diabetes drug

Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved symptoms and physical limitations in patients with heart failure with preserved ejection fraction, according to clinical trial results published in Nature Medicine.

29 Nov 2021

Extended host range for SARS-CoV-2 variants of concern

Researchers used viral pseudotyping to examine whether variants of concern had different host ACE2 receptor usage patterns.

29 Nov 2021

Immunity found 6 months after SARS-CoV-2 infection in children

A new study suggests that infection-induced antibodies persist, providing protection for at least six months.

29 Nov 2021

Do we need COVID-19 vaccine boosters?

An article published recently in the Journal of Virology explored the science behind COVID-19 vaccine boosters.

29 Nov 2021

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

29 Nov 2021

Study suggests making COVID vaccines based on Mu variant

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant (B.1.621, B.1.621.1) has been tagged as a Variant Being Monitored (VBM), and as of August 30, 2021, it had been detected in 39 countries.

28 Nov 2021

Identifying the spread of novel B.1.1.523 SARS-CoV-2

In their recent study, researchers from Lithuania have reported the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant lineage B.1.1.523 containing a set of mutations associated with immune escape, including deletion 156_158del, substitution E484K and S494P in Spike (S) protein.

28 Nov 2021

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known as interferon, allowing for the mitigation of coronavirus disease (COVID-19) severity. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

28 Nov 2021